Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
Status:
Completed
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
This is an integrated Phase 1, single centre, multi-part, open-label study in both healthy
subjects (Part 1), subjects with mild stable asthma (Part 2) and subjects with mild to
moderate stable asthma (Part 3). In all parts of the study (i.e. Parts 1, 2 and 3) every
effort will be made to include as close as possible an equal balance between male and female
subjects; in Part 1 and Part 2 this will be in each of the individual cohorts.
Safety, tolerability and PK will be assessed following either single ascending (SAD) or
multiple ascending (MAD) dosing of ZP-059; Part 1 and Part 2, respectively.